Abstract 2200P
Background
Mediastinal neoplasms are typical but uncommon thoracic diseases with increasing incidence and unfavorable prognoses. A comprehensive understanding of their spatiotemporal distribution is essential for accurate diagnosis and timely treatment. However, previous studies are limited in scale and data coverage. Therefore, we delineate the distribution of mediastinal lesions within a substantial, nationwide, multi-institutional cohort, thereby providing valuable insights into this disease.
Methods
In this multi-center, hospital-based, observational study, we included 20 hospitals from 11 provinces in China. At each institution, a standardized retrospective search of electronic medical records between Jan. 1st, 2009 and Dec. 31st, 2020 was performed. We collected information on sociodemographic characteristics, CT images, and pathologic diagnoses. The incidence of mediastinal neoplasms was analyzed in terms of age, sex, time, compartment, and geographical region.
Results
Among 7,829 cases, the most common mediastinal lesions were thymomas (30.6%), benign mediastinal cysts (23.3%), and neurogenic tumors (10.0%). The distribution of these lesions varied significantly among mediastinal compartments, with thymomas (39.6%), benign cysts (28.0%), and neurogenic tumors (51.7%) being the most commonly observed lesions in the prevascular, visceral, and paravertebral mediastinum, respectively (P < 0.001). The occurrence of mediastinal lesions varied by age, with germ cell tumors being more frequently observed in patients younger than 18 and those aged 18-29 years, whereas thymomas occurred more often in patients over 30 (P < 0.001). Also, the lesion location was associated with age, with patients having paravertebral lesions being the youngest (P < 0.001). Spatial distribution analysis revealed that thymomas were the most common mediastinal lesions across different geographical regions.
Conclusions
This study revealed significant heterogeneity in the spatiotemporal distribution of mediastinal neoplasms. These findings provide useful demographic data when considering the differential diagnosis of mediastinal lesions, and would be beneficial for tailoring disease prevention and control strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07
2194P - Prospective observational study of physical activity measurement using wearable device as an alternative to ECOG PS in patients with advanced lung cancer
Presenter: Kentaro Ito
Session: Poster session 07
Resources:
Abstract
2195P - Targeted gene editing with CRISPR for the treatment of pleural mesothelioma
Presenter: Rodrigo Dominic Cerqueda
Session: Poster session 07
2196P - PET-CT detects response to treatment with ipilimumab and nivolumab in malignant mesothelioma far better than CT
Presenter: Daniel C. Christoph
Session: Poster session 07
2197P - Prognostic value of 18F-FDG-PET for patients with malignant pleural mesothelioma treated with double immunotherapy
Presenter: Solfrid Thunold
Session: Poster session 07
2198P - Clinicopathologic characteristics and outcomes to immune checkpoint inhibitor therapy in patients with HER2-altered metastatic non-small cell lung cancer
Presenter: Maisam Makarem
Session: Poster session 07
2199P - Immunohistochemical identification of clinical subtypes and potential therapeutic vulnerabilities of lung carcinoids based on multi-omic analysis
Presenter: Jules Derks
Session: Poster session 07
2201P - Malignant pleural mesothelioma (MPM)-specific DNA methylation patterns in patients using liquid biopsies
Presenter: Sabine Schmid
Session: Poster session 07
2202P - Large cell neuroendocrine carcinoma (LCNEC) subtyping based on NEUROD1, ASCL1, POU2F3 and YAP1 expression
Presenter: Frank Heijboer
Session: Poster session 07
2203P - Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
Presenter: Mario Occhipinti
Session: Poster session 07